Chemomab Therapeutics Ltd
CMMB
查看详细走势图
1.890USD
-0.030-1.56%
收盘 12/19, 16:00（美东）报价延迟15分钟
46.53M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.56%
5天
-14.86%
1月
-22.22%
6月
-60.63%
今年开始到现在
-73.90%
1年
-71.88%
查看详细走势图
TradingKey Chemomab Therapeutics Ltd股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Chemomab Therapeutics Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
强力买入
评级
26.500
目标均价
+867.15%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Chemomab Therapeutics Ltd亮点
亮点风险
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
估值高估
公司最新PE估值-1.57，处于3年历史高位
机构加仓
最新机构持股1.06M股，环比增加8.03%
Chemomab Therapeutics Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Chemomab Therapeutics Ltd简介
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
公司代码CMMB
公司Chemomab Therapeutics Ltd
CEOMor (Adi)
网址https://www.chemomab.com/
常见问题
Chemomab Therapeutics Ltd(CMMB)的当前股价是多少？
Chemomab Therapeutics Ltd(CMMB)的当前股价是 1.890。
Chemomab Therapeutics Ltd的股票代码是什么？
Chemomab Therapeutics Ltd的股票代码是CMMB。
Chemomab Therapeutics Ltd股票的52周最高点是多少？
Chemomab Therapeutics Ltd股票的52周最高点是9.840。
Chemomab Therapeutics Ltd股票的52周最低点是多少？
Chemomab Therapeutics Ltd股票的52周最低点是1.910。
Chemomab Therapeutics Ltd的市值是多少？
Chemomab Therapeutics Ltd的市值是46.53M。
Chemomab Therapeutics Ltd的净利润是多少？
Chemomab Therapeutics Ltd的净利润为-13.95M。
现在Chemomab Therapeutics Ltd(CMMB)的股票是买入、持有还是卖出？
根据分析师评级，Chemomab Therapeutics Ltd(CMMB)的总体评级为--，目标价格为26.500。
Chemomab Therapeutics Ltd(CMMB)股票的每股收益（EPS TTM）是多少
Chemomab Therapeutics Ltd(CMMB)股票的每股收益（EPS TTM）是-0.547。
相关品种
